Piramal Pharma Q4 net profit jumps 52% to ₹154 crore; revenue up 8%, dividend declared

Piramal Pharma Ltd on Wednesday (May 14) reported a 51.5% year-on-year (YoY) jump in net profit at ₹153.5 crore for the fourth quarter that ended March 31, 2025.

In the corresponding quarter of the previous fiscal, Piramal Pharma posted a net profit of ₹101.3 crore, the company said in a regulatory filing. The company's revenue from operations increased 7.9% to ₹2,754 crore as against ₹2,552.4 crore in the corresponding period of the preceding fiscal.

At the operating level, EBITDA was up 5.9% to ₹561 crore in the fourth quarter of this fiscal over ₹529.9 crore in the corresponding period in the previous fiscal.

Also Read: Piramal Pharma shares rise 4% after US expansion plans, Turbhe clearance

EBITDA margin stood at 20.45% in the reporting quarter as compared to 20.8% in the corresponding period in the previous fiscal. EBITDA is earnings before interest, tax, depreciation, and amortisation.

Piramal Pharma’s net-debt-to-EBITDA ratio improved to 2.7x in FY25 from 5.6x in FY23. In its Contract Development and Manufacturing Organisation (CDMO) segment, innovation-related work contributed 54% of revenues in FY25, up from 50% in FY24, driven by the commercial manufacturing of on-patent molecules.

Revenues from on-patent commercial manufacturing grew over 50% year-on-year to $179 million, compared to $116 million in FY24 and $53 million in FY23. Differentiated offerings contributed 49% of CDMO revenues, with a 28% year-on-year growth. The API generics business also saw healthy growth.

Also Read: Piramal Pharma shares surge 20% after management guides for doubling revenue by FY30

In the India Consumer Healthcare (ICH) segment, revenues crossed the ₹1,000 crore milestone in FY25. Power Brands posted 20% growth year-on-year, contributing 49% to ICH sales, and excluding the i-range (impacted by regulatory price control), the segment recorded 26% growth. Piramal Pharma launched 21 new products and 31 new SKUs during the year.

E-commerce sales rose 39% year-on-year, accounting for 21% of ICH sales, with the brand present across more than 20 e-commerce platforms. The Board has recommended a final dividend of ₹0.14 per equity share of ₹10 each for FY25, subject to shareholder approval at the upcoming Annual General Meeting.

The results came after the close of the market hours. Shares of Piramal Pharma Ltd ended at ₹219.00, up by ₹4.10 or 1.91% on the BSE.

Also Read: Piramal Pharma Q3 Results | Net profit tanks 63% to ₹4 crore, revenue climbs 13% to ₹2,204 crore